Masimo Shareholders Face Scrutiny Over $180-per-Share Sale to Danaher
Event summary
- Law firm Wohl & Fruchter LLP has initiated an investigation into the fairness of Masimo Corporation’s proposed acquisition by Danaher Corporation.
- The deal, announced recently, values Masimo at $180 per share in cash.
- This price is significantly below price targets from several Wall Street analysts, including Jason Bednar (Piper Sandler - $210), Vik Chopra (Wells Fargo - $190), and Jayson Bedford (Raymond James - $185).
- The $180 price also sits below Masimo’s 52-week high of $194.88 per share.
- The investigation will focus on whether the Masimo board acted in the best interests of shareholders and if all material information was disclosed.
The big picture
The investigation highlights a growing trend of shareholder activism challenging acquisition terms, particularly when deal prices appear significantly below analyst expectations and prior market valuations. This case underscores the increasing scrutiny boards face in ensuring they act in the best interests of shareholders during M&A transactions, especially given the current environment of higher interest rates and potentially constrained capital markets. The $15.5 billion deal size makes it a significant event with potential ramifications for corporate governance practices across the medical device industry.
What we're watching
- Governance Dynamics
- The outcome of the investigation will likely influence board oversight practices at Masimo and potentially other medical device companies facing similar acquisition pressures.
- Valuation Risk
- Danaher’s ability to justify the acquisition price and integrate Masimo’s technology will be closely scrutinized, as a perceived undervaluation could trigger further shareholder action.
- Litigation Landscape
- The success or failure of Wohl & Fruchter’s investigation could set a precedent for future shareholder lawsuits challenging acquisition terms in the healthcare sector.
